Legend Hony Acquires Stake In Guangzhou Consun Pharmaceutical
This article was originally published in PharmAsia News
Legend Hony, a private investment arm of Legend Holdings, has announced that it will become a minority shareholder of Guangzhou Consun Pharmaceutical with its injection of 180 million yuan into the firm. This is Legend Hony's third foray into the pharmaceutical industry after its investment in Simcere Pharmaceutical Group and buyout of Shijiazhuang Pharmaceutical. Consun is a leading TCM drug maker for kidney diseases. Company officials disclosed that the firm intends to list in the A-share market in the near future, the probability which will be increased by Hony's partnership. The equity investor is consolidating its pharmaceutical resources to maximize its capital value. (Click here for more - Chinese language)
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.